Allan Camaisa co-founded Calidi Biotherapeutics in 2014 and has served as CEO and Chairman of the Board since 2018. He was an early investor in Calidi, and determined to bring a cure for difficult-to-treat cancers to market after losing his own father to cancer. Allan has nearly a decade of experience in oncology and has successfully guided the clinical and preclinical development of Calidi’s NeuroNova and SuperNova platforms. Allan has led multiple financing rounds steering the company to a public listing, while successfully negotiating license agreements with pharmaceutical companies, California Institute of Regenerative Medicine (CIRM) grants, and National Institute of Health collaborations.
Previously, Allan was the CEO and Chairman of Parallel6, Inc., a digital mobile/cloud software platform for managing pharmaceutical clinical trials. In 2005, Allan founded Anakam, Inc., a software security company focused on healthcare, which safeguarded digital medical records through a platform that delivered government-level multifactor authentication and security. Prior to Anakam, Allan founded High Technology Solutions (HTS), a software systems integrator that he grew from two people to more than 500 employees and $50 million in revenue. Before entering business, Allan served eight years as a surface warfare officer in the United States Navy, graduating from the United States Naval Academy and the prestigious Owners Management Program at Harvard Business School.
